Skip to content
ppharmaranks
Menu
Class IIOngoing

Metoprolol Tartrate Tablets USP recall

FDA recall D-0517-2024 · initiated May 6, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Jun 5, 2024How we research

Rubicon Research Private Limited recalled Metoprolol Tartrate Tablets USP in May 2024 — an FDA Class II recall (D-0517-2024) because Presence of Foreign Substance: metal in tablet.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Presence of Foreign Substance: metal in tablet

Something got into the product

A physical or chemical contaminant was found — glass or metal fragments, or a solvent that should not be there.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot 231037H1, exp 6/2027

Quantity recalled: 11,664 Bottles

Details

Product
Metoprolol Tartrate Tablets USP, 25mg, 1000 count bottle, Rx only, distributed by: TruPharma, LLC, Tampa, FL 33609, Manufactured by: Rubicon Research Private Limited, Ambernath Dist Thane 421506 India, NDC 52817-360-00
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide
Initiated
May 6, 2024
FDA report date
Jun 5, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Metoprolol Tartrate Tablets USP recalled?
Rubicon Research Private Limited recalled Metoprolol Tartrate Tablets USP in May 2024 — an FDA Class II recall (D-0517-2024) because Presence of Foreign Substance: metal in tablet. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Metoprolol Tartrate Tablets USP recalled?
Per the FDA enforcement record, the reason for recall D-0517-2024 was: Presence of Foreign Substance: metal in tablet
Is a recalled Metoprolol Tartrate Tablets USP dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Metoprolol Tartrate Tablets USP are affected?
Distributed: Nationwide. The recall covers these lots — Lot 231037H1, exp 6/2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0517-2024.

Source: openFDA Drug Enforcement record D-0517-2024

← All drug recalls